Clinical Trial Detail

NCT ID NCT03197935
Title A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

triple-receptor negative breast cancer

Therapies

Pegfilgrastim

Doxorubicin

Atezolizumab

Filgrastim

Nab-paclitaxel

Cyclophosphamide

Age Groups: adult senior

Additional content available in CKB BOOST